{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.9","value":"-5.6"}]}],"title":"Disease Symptoms"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"7.9","value":"6.5"}]}],"title":"Side-effects of Treatment"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"13.6","value":"-5.6"}]}],"title":"Body Image"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.6","value":"1.9"}]}],"title":"Future Perspective"}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"}],"units":"Participants"}],"description":"EORTC QLQ-MY20 is a 20-item questionnaire used in clinical research to assess health-related quality of life in multiple myeloma patients. Questions are answered on a 4-point scale from 1 'Not at All' to 4 'Very Much'.\n\nThe QLQ-MY20 includes four domains (Disease Symptoms, Side-Effects of Treatment, Body Image and Future Perspective).\n\nDomain scores are calculated as averages and transformed to range from 0 to 100.\n\nFor the Disease symptoms and side-effects of treatments scales a higher score represents a higher level of symptoms/problems and a negative change from baseline value indicates reduction (i.e. improvement) in symptoms. For the body image and future perspectives scales a higher score represents a higher level of functioning, and a positive change from baseline indicates improvement.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received carfilzomib administered as an intravenous (IV) infusion twice-weekly for up to six 28-day cycles followed by once-weekly for another six 28-day cycles. The carfilzomib dose was 20 mg/m² on days 1 and 2 of cycle 1, 56 mg/m² for the remaining days of cycle 1 (days 8, 9, 15, and 16) and then on days 1, 2, 8, 9, 15, and 16 of each cycle for cycles 2 to 6, and 70 mg/m² on days 1, 8, and 15 of each cycle for cycles 7 to 12.\n\nParticipants also received dexamethasone either orally or by IV infusion at a dose of 20 mg once daily on days 1, 2, 8, 9, 15, 16, 22, and 23 of cycles 1 to 6 and at a dose 40 mg once daily on days 1, 8, 15 of cycles 7 to 12.","id":"OG000","title":"Carfilzomib Plus Dexamethasone"}],"paramType":"MEAN","populationDescription":"All enrolled and treated participants","reportingStatus":"POSTED","timeFrame":"Baseline (cycle 1 day 1) and cycle 12 day 1","title":"Change From Baseline to Last Cycle of Treatment in EORTC QLQ Multiple Myeloma Module (MY-20) Scores","type":"SECONDARY","unitOfMeasure":"scores on a scale"}